NCT04268069View on ClinicalTrials.gov

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

October 5, 2020

Study Completion Date

October 5, 2020

Conditions
Dry Eye Disease
Interventions
DRUG

PL9643 Ophthalmic Solution

PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.

DRUG

Placebo Ophthalmic Solution

Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.

Trial Locations (4)

28150

Vita Eye Clinc, Shelby

38119

Total Eye Care, P.A., Memphis

01810

Andover Eye Associates, Andover

02767

Andover Eye Associates, Raynham

Sponsors

Collaborators (1)

Palatin Technologies, Inc
All Listed Sponsors
collaborator

Palatin Technologies, Inc

INDUSTRY

lead

ORA, Inc.

INDUSTRY